STOCK TITAN

Syndax Pharmaceuticals (SNDX) Stock News, Mar-Jun 2023

SNDX NASDAQ

Syndax Pharmaceuticals reports developments as a commercial-stage biopharmaceutical company advancing cancer therapies. Company updates center on Revuforj (revumenib), an FDA-approved menin inhibitor, and Niktimvo (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 receptor.

Recurring news includes quarterly financial results, product revenue for Revuforj and Niktimvo, collaboration revenue from Niktimvo commercialization with Incyte, clinical data presentations in acute leukemia, chronic graft-versus-host disease and related indications, FDA-related product updates, investor conference activity and inducement equity grants under Nasdaq listing rules.

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.08%
Tags
none
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.33%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.55%
Tags
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.10%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.38%
Tags
conferences earnings
-
Rhea-AI Summary

Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company focused on cancer therapies, announced an inducement stock option grant for its new President, Dr. Neil Gallagher. Effective April 10, 2023, Dr. Gallagher received an award to purchase 250,000 shares at an exercise price of $19.35, the closing stock price on that date. The stock options will vest over four years, with 25% vesting after one year and the remainder vesting monthly thereafter, contingent on Dr. Gallagher's continued employment. This grant was approved by Syndax's Board of Directors in accordance with NASDAQ Listing Rule 5635(c)(4). Syndax's innovative pipeline includes drugs like revumenib and axatilimab, which are in pivotal trials. Further details can be found on their official website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.99%
Tags
none
Rhea-AI Summary

Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a biopharmaceutical company focused on cancer therapies, announced on April 3, 2023, the granting of inducement awards to six new employees under its 2023 Inducement Plan. These awards total 121,100 shares of common stock, with an exercise price set at $20.91 per share, reflecting the closing stock price on that date. The options will vest over four years, with 25% vesting after one year and the remainder vesting monthly thereafter, contingent upon the employees’ continued service. Syndax's notable pipeline includes revumenib and axatilimab, both currently in pivotal trials.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.96%
Tags
none
-
Rhea-AI Summary

Syndax Pharmaceuticals (Nasdaq: SNDX) has appointed Neil Gallagher, M.D., Ph.D., as President and Head of Research and Development, effective April 10, 2023. With over 20 years in oncology drug development, including roles at AbbVie and Novartis, Gallagher aims to enhance the company’s pipeline, notably revumenib and axatilimab, both in pivotal trials. CEO Michael A. Metzger praised Gallagher's experience, particularly in securing drug approvals. The transition follows the prior president's shift to the Board of Directors, indicating a strategy for growth and innovation in targeted oncology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.13%
Tags
management
-
Rhea-AI Summary

Syndax Pharmaceuticals (SNDX) announced the publication of Phase 1 data from its AUGMENT-101 trial of revumenib for treating nucleophosmin mutant (mNPM1) and KMT2A-rearranged (KMT2Ar) relapsed/refractory acute leukemia in Nature. The study involved 68 patients, with 60 evaluable for efficacy. Results showed a 53% overall response rate (32/60) and 30% CR/CRh (18/60). Revumenib was well-tolerated, with no treatment-related discontinuations. The company anticipates topline data from the pivotal trial by Q3 2023 and plans to file a New Drug Application by year-end, potentially positioning revumenib as the first approved menin inhibitor.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.90%
Tags
Rhea-AI Summary

Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) announced on March 6, 2023, the granting of stock options for 15,200 shares to a new employee under their 2023 Inducement Plan. The options have an exercise price of $24.86, closing on March 1, 2023. The vesting schedule includes 25% vesting on the one-year anniversary, with the remaining shares vesting monthly over three years, contingent upon continued employment. Syndax focuses on developing cancer therapies including innovative drugs like revumenib and axatilimab, which are currently in pivotal trials.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.57%
Tags
none

FAQ

What is the current stock price of Syndax Pharmaceuticals (SNDX)?

Syndax Pharmaceuticals (SNDX) last closed at $9.20.

What is the market cap of Syndax Pharmaceuticals (SNDX)?

The market cap of Syndax Pharmaceuticals (SNDX) is approximately $828.3M.